FAPD

NeurAxis Reports Third Quarter 2023 Financial Results

Retrieved on: 
월요일, 11월 20, 2023
Policy, Adolescence, Research, Neuraxis, Percutaneous, Hospital, Record, Abdominal pain, RED, Disability, University, Cyproheptadine, Growth, Publication, Patient, CareFirst BlueCross BlueShield, Amitriptyline, FAPD, Video game

CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.

Key Points: 
  • CARMEL, Ind., Nov. 20, 2023 (GLOBE NEWSWIRE) -- NeurAxis, Inc. (NYSE American: NRXS) (“NeurAxis” or the “Company”), a medical technology company commercializing neuromodulation therapies that address chronic and debilitating conditions in children and adults, today reported financial results for the third quarter ended September 30, 2023.
  • Gross margin totaled 85.9% in the third quarter of 2023, compared to 89.1% in the third quarter of 2022.
  • Selling expenses for the third quarter of 2023 were $64.2 thousand, compared to $81.6 thousand in the third quarter of 2022.
  • General and administrative expenses for the third quarter of 2023 were $3,323.4 thousand, compared to $1,586.5 thousand in the third quarter of 2022.

NeurAxis Announces Results of Comparative Study of IB-Stim™ and Standard Medical Therapy in Adolescents with Functional Abdominal Pain Disorders

Retrieved on: 
화요일, 9월 26, 2023
International Classification of Functioning, Disability and Health, Neuraxis, Comparison, Cyproheptadine, FAPD, API, Clinical trial, Amitriptyline, Abdominal pain, FDI, Disability, Patient, Journal of Pain Research, Children's Hospital & Medical Center, Adolescence, Cincinnati, NSS, NYSE, Medical imaging

Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD.

Key Points: 
  • Led by the Cincinnati Children’s Hospital Medical Center, the comparative study concluded that IB-Stim™ may be a good non-pharmacologic alternative for FAPD.
  • The publication , Percutaneous electrical nerve field stimulation compared to standard medical therapy in adolescents with functional abdominal pain disorders, featured in the September 19th 2023 Frontiers in Pain Research, reviewed records of 101 adolescents treated with 4 weeks of IB-Stim™, amitriptyline or cyproheptadine.
  • In the study, 59% of patients in the IB-Stim group had failed prior standard medical therapy.
  • Dr. Adrian Miranda, Chief Medical Officer of NeurAxis, said, “It is exciting to see a comparative evaluation of IB-Stim™ with standard medical therapy.